Sperobes like David K. Hong, MD, our Vice President of #ClinicalDevelopment, are committed to developing antibiotics like tebipenem to treat complicated urinary tract infections (#cUTI). These innovations could potentially reduce the need for hospitalization or long-term intravenous therapy. We aim to bring hope to patients and improve their quality of life. #SpeakingSpero
Spero Therapeutics
Biotechnology Research
Cambridge, MA 13,645 followers
Multi-Asset, clinical-stage biotech company focused on multidrug-resistant bacterial infections and rare disease
About us
We are a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for bacterial infections, including multi-drug resistant, or MDR, bacterial infections, and rare diseases. Spero’s lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease, a rare orphan disease. Spero’s partnership directed programs consist of SPR206 and tebipenem HBr, which through the company’s business development efforts, have joint venture relationships supporting their ongoing development. SPR206, is an IV-administered agent being developed as an innovative option to treat MDR Gram-negative bacterial infections, in the hospital setting. Tebipenem HBr, is designed to be the first broad-spectrum oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections, or cUTIs, including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. We believe that our novel product candidates will have a meaningful impact on patient health and significant commercial applications for treating MDR infections in hospitals and community settings.
- Website
-
http://www.sperotherapeutics.com
External link for Spero Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Cambridge, MA
- Type
- Public Company
- Founded
- 2013
- Specialties
- Antibacterial Therapies, Novel Therapeutics, and Infectious Disease
Locations
-
Primary
Get directions
675 Massachusetts Ave
14th Floor
Cambridge, MA 02139, US
Employees at Spero Therapeutics
Updates
-
🎒 Sperobes partnered with Life Science Cares Boston and HopeWell Inc to support children in foster care. We prepared backpacks and supplies for students at the West End House, making their back-to-school season brighter. Click here to support the children of West End House: https://bit.ly/4dqs2xC #DoingGood
-
-
Today, we announced our second quarter financial results for 2024. We take pride in serving our patients and developing beneficial treatment options for #RareDiseases and #InfectiousDiseases. Read more in our press release here: https://bit.ly/3YxrhP5
-
-
🫁🌍 Spero is a proud sponsor of #WorldNTMAwarenessDay! We Sperobes are committed to advancing research and #NTM treatments to improve patient outcomes. Join us in spreading awareness and advocating for those affected by the disease. Learn more on our therapeutic approach here: https://lnkd.in/gXCw-Sz4.
-
Nontuberculous Mycobacterium (#NTM), caused by environmental pathogens which lead to progressive lung damage and respiratory failure, is on the rise globally. At Spero, we are developing SPR720, a broad-spectrum candidate that potentially represents a novel class of antibacterial agents to treat #NTMPD. Learn more here: https://bit.ly/3xOrLFF
-
-
In this #PhysicianQandA, Dr. Kenneth Olivier shares common issues his patients experience when dealing with #NTM and other related conditions. Our goal is to bring hope to patients and physicians like Dr. Olivier as they navigate their diagnosis and treatment journey. Watch the full video on our website: https://bit.ly/3XVmeHX
-
In case you missed it, Spero is included in the latest World Health Organization World Health Organization report on antibacterial #DrugDevelopment. The fight against antimicrobial resistance (#AMR) is more important than ever, and as a small company tackling this significant challenge, we are proud to be contributing to an area of vast unmet need. Read the full report here: https://bit.ly/4biWZm8
-
🌍 Today is #WorldBronchiectasisDay! Let's raise awareness about this chronic lung condition affecting millions. At Spero we hope to raise awareness about this chronic lung condition by educating patients and clinicians. Spero is doing the important work of conducting research in this area of unmet need to advance new therapies and show compassion to bronchiectasis patients. Learn more from COPD Foundation: https://bit.ly/3XMCcUP. #WorldBronchiectasisDay2024
-
-
We're gearing up for an exciting time at the 7th Annual World Bronchiectasis & NTM Conference 2024 in Dundee, Scotland, where we'll explore cutting-edge insights and participate in discussions around the future of #NTM care. Check out the event details here: https://bit.ly/4b9axAs
-